Scientific Knowledge on the Subject: TB is the leading cause of mortality in HIV-infected persons and is frequently associated with a delay in diagnosis, in part due to limitations of currently available tests, particularly in high HIV prevalence settings. The microscopicobservation drug-susceptibility (MODS) assay is a simple, rapid, low-cost method for diagnosis of TB and multidrug-resistance. However, no studies have been performed in sub-Saharan African settings with a high prevalence of TB/HIV co-infection and multidrug resistance. 
INTRODUCTION
Tuberculosis (TB) is a leading cause of morbidity and mortality among HIV-infected patients worldwide. In sub-Saharan Africa, the TB and HIV epidemics are closely intertwined, with more than 70% of all TB cases in South Africa co-infected with HIV.(1,2) Diagnosing TB in HIV-infected patients is challenging because of not only the atypical clinical presentation of TB disease, but also the paucibacillary nature of pulmonary TB disease in HIV patients. The most widely-used TB diagnostic test worldwide is sputum smear microscopy, which fails to detect TB in over 60% of cases, particularly in high HIV prevalence settings.(3-6) Smearnegative TB in HIV-infected persons is associated with poorer outcomes, in part due to delays in TB diagnosis and treatment initiation. (7, 8) Although mycobacterial culture can provide added diagnostic sensitivity, the vast majority of TB suspects lack access to this, given the need for sophisticated and expensive laboratories. There is an urgent need for simple, rapid, affordable diagnostic tests, more sensitive than smear microscopy, which can be used for TB diagnosis in resource-limited, high HIV prevalence settings. (9, 10) In addition to the rapid rise in drug-susceptible TB incidence in sub-Saharan Africa, mulitdrug-resistant (MDR) TB has recently emerged as a growing cause of mortality among TB/HIV co-infected patients. (11, 12) Diagnosis of MDR-TB requires microbiologic evaluation of the M.tuberculosis isolate's drug-susceptibility, which is not possible with smear microscopy and, instead, requires mycobacterial culture. Of limited availability in many areas most burdened by MDR-TB, current techniques for DST are further complicated by turnaround times of [6] [7] [8] weeks. This long delay results in disease progression, and often death among HIV co-infected patients, (13, 14) in addition to ongoing transmission of MDR-TB strains in healthcare and community settings. A better diagnostic test for MDR-TB that has a faster turnaround-time, and Page 6 of 35 that can be implemented in peripheral healthcare settings, affording accessibilty to a substantially larger proportion of the population is needed.
In recent years, several rapid assays for TB diagnosis have been developed. (15, 16) The microscopic-observation drug-susceptibility (MODS) assay is a simple, rapid, low-cost method which holds great promise for resource-limited settings.(17-21) MODS detects TB and drug resistance directly from sputum using liquid broth media, and has been found to be highlysensitive and specific in rapidly detecting TB and MDR-TB compared with conventional liquid culture. However, these studies have not been performed in sub-Saharan African settings with a high prevalence of TB/HIV co-infection.
South Africa has the largest HIV burden worldwide, (22) and also among the highest TB incidence (948 cases per 100,000 population).(23) Moreover, MDR-TB has recently emerged as a widespread epidemic. (24, 25) In the province of KwaZulu-Natal (KZN), there were over 100,000 cases of TB, including 3000 MDR-TB cases reported in 2007 (30 cases per 100,000 population).(13) Eighty percent of all TB cases and 90% of MDR-TB cases were HIV coinfected. Although mycobacterial culture and DST are available, they are only performed at a single central laboratory in KwaZulu-Natal and take 6-12 weeks for results. Moreover, the vast majority of TB suspects continue to be evaluated by smear microscopy alone, due to current policies that limit culture and DST only to high-risk patients (i.e, treatment failures and retreatment cases). Thus, we evaluated the MODS assay to determine its performance in diagnosis of TB and MDR-TB in a high HIV-prevalence setting. Some of the results of these studies have been previously reported in the form of an abstract.(26)
METHODS
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Study population
Consecutive adult TB suspects were enrolled from inpatient and outpatient settings at a district hospital from June 2008 through April 2009. Study staff actively screened adults for the presence of either cough (any duration) or >2 other TB symptoms (fever, night sweats, weight loss, chest pain, or shortness of breath of any duration). Patients were eligible if they reported symptoms and were new TB suspects (i.e., not currently taking anti-tuberculosis medications) or treatment failures (i.e., receiving anti-TB medications for >2 months, but with recurrence or persistence of TB symptoms).
Sample collection
All subjects submitted a single "spot" sputum sample. Patients diagnosed with TB were offered HIV testing, as per current routine practice at the district hospital. CD4 cell count was obtained on all known HIV-positive patients, either at the time of enrollment or abstracted from the medical chart within one month before or after enrollment.
Laboratory methods
Sputum specimens were transported to the TB research laboratory at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal in Durban for standard culture, DST, and MODS testing within 48 hours of collection. All samples were stored at 4° C prior to and during transport to the laboratory.
M.tuberculosis detection
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The methods for sputum decontamination, culture, and drug-susceptibility testing in this setting have been previously described (27) and are available in the online appendix. Briefly, sputum samples were digested using the N-acetyl-L-cysteine (NALC)-sodium hydroxide (NaOH) method. The re-suspended sediment was divided for parallel testing by MODS MGIT cultures that were contaminated prior to 42 days were re-decontaminated and re-cultured.
All positive cultures by MGIT were identified as M. tuberculosis complex by niacin and nitrate reductase tests.
The MODS assay was performed in accordance with published standard operating procedures, (28) with minor variations noted in the online appendix. For each patient sample, 4 wells were used: 2 drug-free wells, 1 with isoniazid at 0.4 µg/ml, and 1 with rifampicin at 1 µg/ml. MODS cultures were examined using an inverted light microscope at 40x magnification every day from day 4 through day 21. Positive MODS cultures were identified by presence of characteristic cord formation in the drug-free control wells.
Drug-susceptibility testing
Indirect drug-susceptibility testing (DST) was performed on all positive isolates from the standard culture using the 1% proportion method on Middlebrook 7H10 agar to isoniazid (1.0 ug/mL), rifampicin (1.0ug/mL), ethambutol (7.5ug/mL), and streptomycin (2.0ug/mL).
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Direct drug-susceptibility testing was performed with the MODS assay for isoniazid (0.4 ug/mL) and rifampicin (1.0ug/mL). Growth in drug-free control wells but not in drug-containing wells indicated a fully-susceptible strain; growth in drug-free and in a drug-containing well indicated resistance. Drug-sensitive and multidrug-resistant control strains were included on each MODS plate. A subset of MODS cultures did not undergo drug-susceptibility testing, and therefore, only 60 specimens had concurrent MODS isoniazid and rifampin wells for comparison to the 1% proportion method.
Definitions and Outcome Measures
A positive reference result was defined as a positive culture on either Middlebrook or MGIT culture.
The primary outcome measures were sensitivity, specificity, positive predictive value, negative predictive value, and turnaround time of the MODS assay compared to standard reference methods for: 1) detection of M.tuberculosis, and 2) diagnosis of drug-resistant TB.
Turnaround time (TAT) was defined as the time from specimen processing to the time of culture and, if culture-positive, DST result. Secondary outcomes included performance of MODS, stratified by HIV status and sputum smear AFB result.
Statistical analysis
We calculated simple proportions and 95% confidence intervals (CI) for all analyses of sensitivity, specificity, and predictive value. For categorical variables, we compared proportions using chi-square tests and Fisher's exact test. For continuous variables, we compared medians using the Wilcoxon rank-sum Test. Turnaround time (TAT) was determined using survival Data were analyzed using SAS, software version 9 (Cary, NC, USA).
Ethical Considerations
This study was reviewed and approved by the institutional review boards at Albert
Einstein College of Medicine, Yale University, and the University of KwaZulu-Natal, and by the KwaZulu-Natal Department of Health.
RESULTS
Patients and samples
We collected sputum samples from 534 consecutive adult TB suspects, of whom 354 (66%) were female and median age was 38 years (interquartile range [IQR]: 31-48; Table 1 ).
There were 475 (89%) TB suspects with no prior TB history and 59 (11%) who were currently failing to respond to first-line TB treatment. Among persons with known HIV status, 388 (87%)
were HIV-positive and the median CD4 cell count was 161 cells / mm 3 (IQR: 72-307).
Among 534 TB suspects enrolled, 113 (21%) were identified with TB from either solid or liquid culture ( Table 1) . Of these, 63 (56%) were smear-positive and 50 (44%) were smearnegative. Among smear-positive samples, 19 (30%) were graded as scanty or 1+ and 44 (70%)
were 2+ or 3+. Sensitivity did not differ between HIV-positive and HIV-negative patients (88% vs 90%, respectively; p=1.00), nor did specificity (97% vs. 100%, respectively; p=0.37). Negative predictive value for exclusion of TB was high in both groups (96% in HIV-positive, 98% in HIV-negative).
Among the 17 TB cases that were not detected by the MODS assay (i.e., false-negative results), 14 (82%) were smear-negative. Among 13 MODS false-positive results (i.e., reference standard-negative), repeat culture from the original specimen was negative, confirming these 13 as false-positive MODS results. No MODS cultures were contaminated by bacterial or fungal growth.
Direct drug-susceptibility testing for MDR-TB
A subset of MODS cultures did not undergo drug-susceptibility testing, and therefore, only 60 specimens had concurrent MODS isoniazid and rifampin wells for comparison to the 1% proportion method. Among these samples, resistance to isoniazid was detected in 13 (21%), to rifampin in 14 (23%), and to both isoniazid and rifampin (i.e., MDR-TB) in 11 (18%) by the reference standard ( Table 3) . Sensitivity of the MODS assay for detection of resistance to 139 (26) 12 ( 64 (16) 140 (36) 68 (18) 68 (18) 367 (69) 390 (73) 383 (72) 380 ( 50 (44) 63 (56) 19 (30) 44 ( 
Setting
Study subjects were recruited from Tugela Ferry, South Africa, a rural community within KwaZulu-Natal province where the incidence of TB is nearly 1100 per 100,000 population and more than 70% of TB cases are HIV co-infected. Middlebrook agar plates were sealed in CO 2 -permeable bags and incubated in 5% CO 2 at 37°C and read at three weeks and six weeks for M.tuberculosis growth. Cultures that exhibited no growth by 6 weeks, or became contaminated were discarded.
MGIT broth tubes were incubated at 37°C in an automatic incubator and 
